Pemvidutide

Last updated
Pemvidutide
Clinical data
Other namesALT-801; MD-1373; SP-1373
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
UNII
KEGG
Chemical and physical data
Formula C182H275N39O54
Molar mass 3873.421 g·mol−1

Pemvidutide is an experimental dual GLP-1/glucagon receptor agonist for the treatment of MASH, obesity, AUD, and ALD developed by Altimmune, a clinical-stage biopharmaceutical company based in Gaithersburg, Maryland. [1] [2]

The drug reduced LDL-C in a clinical trial [3] and does not require dose titration as with GLP-1 mono agonists. [4] The company's latest Phase 2 trial also showed improvement in MASH combined with significant weight loss. [5]

References

  1. ↑ Beaney, Abigail (30 June 2023). "Obesity: Six trials to watch over the next 12 months". Clinical Trials Arena. Retrieved 5 December 2023.
  2. ↑ Bailey, Clifford J.; Flatt, Peter R.; Conlon, J. Michael (March 2023). "An update on peptide-based therapies for type 2 diabetes and obesity". Peptides. 161 170939. doi: 10.1016/j.peptides.2023.170939 . PMID   36608818.
  3. ↑ Plutzky, Jorge; Harris, M. Scott S; Alonso, Cristina; Suschak, John; Noor, Mustafa; Ortiz, Pablo; Georges, Bertrand; Rader, Daniel J; Roberts, Scot S; Browne, Sarah K (8 November 2022). "Abstract 13440: Effect of Pemvidutide (ALT-801), a Novel GLP-1/Glucagon Dual Receptor Agonist, on Pathogenic Lipid Mediators". Circulation. 146 (Suppl_1). doi:10.1161/circ.146.suppl_1.13440.
  4. ↑ Klein, Samuel; Nestor, John J.; Harris, M. Scott; Suyundikov, Anvar; Casper, Rob; Steele, Staci M.; Payne, Jacques D.; Krishnan, Vyjayanthi; Roberts, M. Scot; Browne, Sarah K. (1 June 2022). "334-OR: Pemvidutide (ALT-801) , a Balanced (1:1) GLP-1/Glucagon Dual Receptor Agonist, Induces Rapid and Marked Weight Loss without the Need for Dose Titration in People with Overweight/Obesity". Diabetes. 71 (Supplement_1). doi:10.2337/db22-334-OR.
  5. ↑ "Altimmune's Stock Sinks on Mixed Phase 2 MASH Results for GLP-1 Drug". Fierce Biotech. 26 June 2025.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.